Literature DB >> 15679483

C-reactive protein as a marker of infection in critically ill patients.

P Póvoa1, L Coelho, E Almeida, A Fernandes, R Mealha, P Moreira, H Sabino.   

Abstract

A prospective, observational study was conducted in a medico-surgical intensive care unit to assess the value of C-reactive protein (CRP), temperature and white cell count (WCC) measurements for the diagnosis of infection in critically ill patients. CRP, temperature and WCC were monitored daily in 76 infected and 36 non-infected patients. Multiple receiver-operating characteristics (ROC) curves were used to compare each parameter for infection diagnosis. The area under the curve (AUC) of CRP was significantly higher than that of temperature (0.93 and 0.75, respectively; p < 0.001). A CRP concentration of >8.7 mg/dL and a temperature of >38.2 degrees C were associated with infection, with a sensitivity of 93.4% and 54.8%, and a specificity of 86.1% and 88.9%, respectively. The ROC curve of WCC showed a poor diagnostic performance. The combination of CRP and temperature increased the specificity for infection diagnosis to 100%. In the subgroup of patients with ventilator-associated pneumonia (n = 48), CRP measurements were more reliable than temperature (AUC 0.92 and 0.78, respectively; p 0.006). The CRP levels in infected patients with sepsis, severe sepsis and septic shock were 15.2 +/- 8.2, 20.3 +/- 10.9 and 23.3 +/- 8.7 mg/dL, respectively (p 0.044). It was concluded that CRP was a better marker of infection than temperature. However, the combination of CRP and temperature measurements further increased the specificity for infection diagnosis, even in the subgroup of patients with VAP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15679483     DOI: 10.1111/j.1469-0691.2004.01044.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  88 in total

1.  Altered levels of soluble CD18 may associate immune mechanisms with outcome in sepsis.

Authors:  T W Kragstrup; K Juul-Madsen; S H Christiansen; X Zhang; J Krog; T Vorup-Jensen; A G Kjaergaard
Journal:  Clin Exp Immunol       Date:  2017-08-07       Impact factor: 4.330

2.  Changing clinical features of odontogenic maxillofacial infections.

Authors:  Lotta Seppänen; Riina Rautemaa; Christian Lindqvist; Anneli Lauhio
Journal:  Clin Oral Investig       Date:  2009-05-16       Impact factor: 3.573

Review 3.  Community-acquired pneumonia: identification and evaluation of nonresponders.

Authors:  João Gonçalves-Pereira; Catarina Conceição; Pedro Póvoa
Journal:  Ther Adv Infect Dis       Date:  2013-02

Review 4.  [Evidence-based interdisciplinary treatment of abdominal sepsis].

Authors:  T Schmoch; M Al-Saeedi; A Hecker; D C Richter; T Brenner; T Hackert; M A Weigand
Journal:  Chirurg       Date:  2019-05       Impact factor: 0.955

5.  Temporal convolutional networks allow early prediction of events in critical care.

Authors:  Finneas J R Catling; Anthony H Wolff
Journal:  J Am Med Inform Assoc       Date:  2020-03-01       Impact factor: 4.497

Review 6.  Biomarkers for ventilator-associated pneumonia: review of the literature.

Authors:  Steven J Palazzo; Terri Simpson; Lynn Schnapp
Journal:  Heart Lung       Date:  2011-03-21       Impact factor: 2.210

Review 7.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

Review 8.  Clinical review: the role of biomarkers in the diagnosis and management of community-acquired pneumonia.

Authors:  Mirjam Christ-Crain; Steven M Opal
Journal:  Crit Care       Date:  2010-02-08       Impact factor: 9.097

9.  Should C-reactive protein concentration at ICU discharge be used as a prognostic marker?

Authors:  Joana Silvestre; Luís Coelho; Pedro Póvoa
Journal:  BMC Anesthesiol       Date:  2010-09-27       Impact factor: 2.217

Review 10.  Biomarkers: a definite plus in pneumonia.

Authors:  Hanssa Summah; Jie-Ming Qu
Journal:  Mediators Inflamm       Date:  2009       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.